Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Tanner

Showing results (291-300 of 335) with videos related to

Pageof 34
Sort By:
Transplantation and Cellular Therapy|January 16, 2023
Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center ExperienceOren Pasvolsky, Mahmoud R Gaballa, Denái R Milton, et al.
British Journal of Haematology|July 6, 2026
Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem cell transplant/transplantation in newly diagnosed multiple myelomaCurtis Marcoux, Denái R Milton, Mark R Tanner, et al.
Blood Cancer Journal|January 10, 2024
Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experienceOren Pasvolsky, Sassine Ghanem, Denái R Milton, et al.
Transplantation and Cellular Therapy|June 9, 2024
Trends in Outcomes After Upfront Autologous Transplant for Multiple Myeloma Over Three DecadesOren Pasvolsky, Curtis Marcoux, Jianliang Dai, et al.
Transplantation and Cellular Therapy|May 18, 2025
Outcomes of Multiple Myeloma Patients With Prior Solid Tumors Undergoing Autologous TransplantationOren Pasvolsky, Curtis Marcoux, Denái R Milton, et al.
Transplantation and Cellular Therapy|August 2, 2025
Outcomes of Patients With Multiple Myeloma With deletion 1p Following Autologous Stem Cell TransplantCurtis Marcoux, Denái R Milton, Mark R Tanner, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|June 4, 2014
Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseasesSandeep Chhabra, Shih Chieh Chang, Hai M Nguyen, et al.
Blood Cancer Journal|November 1, 2024
Optimal infused CD34<sup>+</sup> cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantationOren Pasvolsky, Curtis Marcoux, Denái R Milton, et al.
Bone Marrow Transplantation|December 5, 2025
Results of delayed or salvage autologous hematopoietic stem cell transplantation for multiple myelomaOren Pasvolsky, Curtis Marcoux, Denái R Milton, et al.
Blood Cancer Journal|May 3, 2023
Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patientsOren Pasvolsky, Denái R Milton, Mikael Rauf, et al.
Pageof 34

Showing results (291-300 of 335) with videos related to

Sort By:
Pageof 34
Transplantation and Cellular Therapy|January 16, 2023
Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center ExperienceOren Pasvolsky, Mahmoud R Gaballa, Denái R Milton, et al.
British Journal of Haematology|July 6, 2026
Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem cell transplant/transplantation in newly diagnosed multiple myelomaCurtis Marcoux, Denái R Milton, Mark R Tanner, et al.
Blood Cancer Journal|January 10, 2024
Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experienceOren Pasvolsky, Sassine Ghanem, Denái R Milton, et al.
Transplantation and Cellular Therapy|June 9, 2024
Trends in Outcomes After Upfront Autologous Transplant for Multiple Myeloma Over Three DecadesOren Pasvolsky, Curtis Marcoux, Jianliang Dai, et al.
Transplantation and Cellular Therapy|May 18, 2025
Outcomes of Multiple Myeloma Patients With Prior Solid Tumors Undergoing Autologous TransplantationOren Pasvolsky, Curtis Marcoux, Denái R Milton, et al.
Transplantation and Cellular Therapy|August 2, 2025
Outcomes of Patients With Multiple Myeloma With deletion 1p Following Autologous Stem Cell TransplantCurtis Marcoux, Denái R Milton, Mark R Tanner, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|June 4, 2014
Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseasesSandeep Chhabra, Shih Chieh Chang, Hai M Nguyen, et al.
Blood Cancer Journal|November 1, 2024
Optimal infused CD34<sup>+</sup> cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantationOren Pasvolsky, Curtis Marcoux, Denái R Milton, et al.
Bone Marrow Transplantation|December 5, 2025
Results of delayed or salvage autologous hematopoietic stem cell transplantation for multiple myelomaOren Pasvolsky, Curtis Marcoux, Denái R Milton, et al.
Blood Cancer Journal|May 3, 2023
Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patientsOren Pasvolsky, Denái R Milton, Mikael Rauf, et al.
Pageof 34